Pharming Group (PHAR) Expected to Announce Earnings on Tuesday

Pharming Group (NASDAQ:PHAR) is anticipated to release its Q3 2026 TU results before the market opens on Tuesday, October 27th. Analysts expect the company to announce earnings of $0.15 per share and revenue of $117.60 million for the quarter. Investors are encouraged to explore the company’s upcoming Q3 2026 TU earnings report for the latest details on the call scheduled for Thursday, October 22, 2026 at 1:00 AM ET.

Pharming Group (NASDAQ:PHAR) last announced its earnings results on Thursday, July 30th. The company reported $0.02 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.06 by ($0.04). Pharming Group had a return on equity of 3.40% and a net margin of 2.51%. On average, analysts expect Pharming Group to post $0.32 EPS for the current fiscal year and $0.28 EPS for the next fiscal year.

Pharming Group Stock Performance

Shares of Pharming Group stock opened at $11.20 on Monday. The company has a debt-to-equity ratio of 0.34, a current ratio of 3.01 and a quick ratio of 2.31. Pharming Group has a 1 year low of $9.11 and a 1 year high of $21.34. The company has a market capitalization of $792.74 million, a P/E ratio of 93.33 and a beta of -0.05. The business has a 50 day moving average price of $10.67 and a 200 day moving average price of $12.59.

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on the company. HC Wainwright reiterated a “buy” rating and set a $37.00 target price on shares of Pharming Group in a report on Tuesday, September 22nd. Oppenheimer reissued an “outperform” rating on shares of Pharming Group in a report on Thursday, July 30th. Canaccord Genuity Group set a $38.00 price target on Pharming Group in a report on Wednesday, September 23rd. Wall Street Zen upgraded Pharming Group to a “hold” rating in a research report on Saturday. Finally, Zacks Research lowered Pharming Group from a “hold” rating to a “strong sell” rating in a research note on Friday, July 31st. Three equities research analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $38.67.

Pharming Group Company Profile

Pharming Group N.V. is a biopharmaceutical company headquartered in Leiden, the Netherlands. The company develops and commercializes medicines for rare diseases and operates internationally, serving patients and healthcare providers in North America, Europe and other selected markets.

Pharming’s principal product is Ruconest, a recombinant C1 esterase inhibitor used to treat acute attacks of hereditary angioedema, a rare genetic disorder that can cause potentially serious swelling. The company also markets Joenja (leniolisib), an oral treatment for activated phosphoinositide 3-kinase delta syndrome (APDS), a rare primary immunodeficiency.